

Disclaimer: This document is an English translation of the original document in Japanese and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original in Japanese, the original shall prevail in all respects.



May 7, 2025

To whom it may concern:

Company name Representative	KISSEI PHARMACEUTICAL CO., LTD. Mutsuo Kanzawa, Chairman and CEO (Stock code 4547; Prime Market, Tokyo Stock Exchange)
Contact	Takahide Kitahara, Managing Director, Department Manager of Corporate Finance and Management Department, CFO (Telephone +81-263-25-9081)

Notice Concerning Dividends of Surplus (Increase in Dividend)

KISSEI PHARMACEUTICAL CO., LTD. (the “Company”) hereby announces that it has resolved at a meeting of its Board of Directors held on May 7, 2025 to pay dividends of surplus with a record date of March 31, 2025 as described below.

This matter is scheduled to be officially decided upon approval at the Annual General Meeting of Shareholders of the Company to be held on June 24, 2025.

Particulars

1. Details of year-end dividend for the fiscal year ended March 31, 2025

	Determined amount	Most recent dividend forecast (May 7, 2024)	Actual results for the previous fiscal year (Fiscal year ended March 31, 2024)
Record date	March 31, 2025	Same as left	March 31, 2024
Dividend per share (Yen)	55.00	45.00	41.00
Total amount of dividends	¥2,354 million	—	¥1,812 million
Effective date	June 25, 2025	—	June 26, 2024
Source of dividends	Retained earnings	—	Retained earnings

2. Reason

The Company has successfully transitioned from the patent cliff to a growth phase under the previous mid-term management plan, “PEGASUS,” achieving a growth trajectory as planned and concluding the final fiscal year ending March 2025 with increased revenue and profit. Today, the Company has announced new mid-term management plan, “Beyond 80,” which places shareholder returns as a key pillar. Over the next five years, the Company plans to allocate a total of 57 billion yen for shareholder returns, comprising dividends and share buybacks, with dividends targeting a payout ratio of 40% or higher, amounting to 27 billion yen.

In gratitude for the support of shareholders during the “PEGASUS” and in consideration of the financial

performance for the fiscal year ending March 2025, the Company has resolved year-end dividend to ¥55 per share, an increase of ¥10 from the previous forecast, resulting in an annual dividend of ¥100 per share.

Regarding the distribution of profit for the next fiscal year, the Company plans to pay a full-year dividend of ¥120 per share, comprising an interim cash dividend of ¥60 and a year-end cash dividend of ¥60.

(Reference) Breakdown of annual dividends per share

(Yen)

Record date	Dividend per share		
	Second quarter-end	Fiscal year-end	Total
Forecast for the next fiscal year (March 31,2026)	60.00	60.00	120.00
Actual results for the current fiscal year (March 31,2025)	45.00	55.00	100.00
Actual results for the previous fiscal year (March 31,2024)	41.00	41.00	82.00

-End-